Rachel Reiff
Profile
Rachel Reiff worked as the Head of Corporate Communications at Aratana Therapeutics, Inc.
Former positions of Rachel Reiff
| Companies | Position | End |
|---|---|---|
| ARATANA THERAPEUTICS INC | Public Communications Contact | 2019-09-30 |
Experiences
Positions held
Linked companies
| Private companies | 1 |
|---|---|
Aratana Therapeutics, Inc.
 Aratana Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aratana Therapeutics, Inc. engages in the development and commercialization of pet therapeutics. Its portfolio includes NOCITA, ENTYCE, and GALLIPRANT. NOCITA (bupivacaine liposome injectable suspension) acts as a local post-operative analgesia for cranial cruciate ligament surgery in dogs, and as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats. ENTYCE(capromorelin oral solution) is intended for appetite stimulation in dogs. GALLIPRANT (grapiprant tablets) is for the control of pain and inflammation associated with osteoarthritis in dogs. The company was founded by Linda Rhodes and Steven St. Peter on December 1, 2010 and is headquartered in Leawood, KS. | Health Technology |
- Stock Market
- Insiders
- Rachel Reiff
